AstraZeneca PLC (AZN)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 12,824.00 |
|---|---|
| 52-week range | 9,892.00 – 15,732.00 |
| Return, 1 month / 3 months | +3.2% / +1.7% |
| Return, 1 year / 3 years | +4.4% / +34.8% |
| Trend | Below its 200-day average |
| RSI (14) | 60 |
| Volatility (1 year) | 26.7% |
| Worst drawdown (1 year) | -26.0% |
| Average daily value traded | 40,262.38M GBX |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AstraZeneca is a pharmaceutical company based in Cambridge, England, that discovers, develops and sells prescription medicines. Its business focuses on therapy areas such as cancer, cardiovascular and metabolic disease, respiratory illness and immunology. The company supplies hospitals, clinics, physicians and health systems in markets around the world, and it also produces vaccines and other biologic treatments through its research and manufacturing operations.
The shares are listed on the London Exchange in UK under the code AZN, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AstraZeneca PLC (AZN) trades on the London Exchange in UK. It last closed at GBX 12,824.00 on 23 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,703 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.4% and over the last three months it rose 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.0% | ||
| From 52-week high | -17.5% | ||
| Momentum | 46 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 1.7% | ||
| 6-month return | -10.9% | ||
| 12-month return, skipping the last month | 1.2% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.0% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 40,262.38M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.0% |
|---|---|
| 1 month | +3.2% |
| 3 months | +1.7% |
| 6 months | −10.9% |
| 1 year | +4.4% |
| 3 years | +34.8% |
| 5 years | +58.2% |
Signals
| 50-day / 200-day average | 12,177.52 / 13,362.01 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 303.31 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.7950 |
| 19 Feb 2026 | GBP 1.5950 |
| 7 Aug 2025 | GBP 0.7670 |
| 20 Feb 2025 | GBP 1.6800 |
| 8 Aug 2024 | GBP 0.7760 |
| 22 Feb 2024 | GBP 1.5600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.